

IPAR



**Public Assessment Report for a
Medicinal Product for Human Use**

Scientific Discussion

Brodilaten 1.25 mg/2.5 ml Nebuliser solution
SALBUTAMOL SULFATE
PA1122/024/001

The Public Assessment Report reflects the scientific conclusion reached by the Health Products Regulatory Authority (HPRA) at the end of the evaluation process and provides a summary of the grounds for approval of a marketing authorisation for a specific medicinal product for human use. It is made available by the HPRA for information to the public, after deletion of commercially sensitive information. The legal basis for its creation and availability is contained in Article 21 of Directive 2001/83/EC, as amended. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the medicinal product for marketing in Ireland.

CONTENTS

- I. INTRODUCTION
- II. QUALITY ASPECTS
- III. NON-CLINICAL ASPECTS
- IV. CLINICAL ASPECTS
- V. OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT
- VI. REVISION DATE
- VII. UPDATE

I. INTRODUCTION

This product was initially authorised under procedure number UK/H/6558/001-003/DC with the UK as RMS. The responsibility of RMS was transferred to Ireland on 11th February 2019 under procedure number IE/H/0713/001-003/DC

Please note the following detail for the product in IE:

Marketing Authorisation Number: PA1122/024/001-003

Marketing Authorisation Holder: Noridem Enterprises Ltd

The current Summary of Product Characteristics (SmPC) for this medicinal product is available on the HPRA website at www.hpra.ie.

The UK public assessment report published at the time of the initial marketing authorisation is provided herein.

Based on the review of the data on quality, safety and efficacy, the Medicines and Healthcare products Regulatory Agency (MHRA) considered that the applications for Brodilaten 1.25 mg/2.5 mL, 2.5 mg/2.5 mL and 5.0 mg/2.5 mL Nebuliser solution (PL 17589/0015-17) could be approved.

Brodilaten 1.25 mg / 2.5 mL Nebuliser solution is indicated for the treatment of acute severe asthma in children and infants.

Note: Acute severe asthma requires hospital treatment in the intensive care unit.

Brodilaten 2.5 mg/2.5 mL and 5.0 mg/2.5 mL Nebuliser solution are indicated in adults, adolescents and children aged 4 to 11 years. Brodilaten 2.5 mg/2.5 mL and 5.0 mg/2.5 mL Nebuliser solution are not indicated for babies and children under 4 years of age.

Brodilaten 2.5 mg/2.5 mL and 5.0 mg/2.5 mL Nebuliser solution are indicated for treatment of severe acute exacerbations of chronic obstructive pulmonary disease (COPD), and in the treatment of acute severe asthma.

The Reference Member State (RMS) for these procedures was the UK and the Concerned Member States (CMS(s)) were France, Germany, Greece and Ireland.

Salbutamol is a selective β_2 agonist providing short-acting (4-6 hour) bronchodilation with a fast onset (within 5 minutes) in reversible airways obstruction. At therapeutic doses it acts on the β_2 adrenoceptors of bronchial muscle. With its fast onset of action, it is particularly suitable for the management and prevention of asthma attacks.

These applications were submitted under Article 10(3) of Directive 2001/83/EC, as amended, claiming to be hybrid medicinal products. The reference products with a complete dossier that have been authorised for not less than 10 years in the EEA are Ventoline 1.25mg/2.5ml Solution pour inhalation par nebuliseur en recipient unidose, authorised in France to Laboratoire GlaxoSmithKline on 27 February 2001, Ventolin Nebules 2.5mg/2.5ml Solution for inhalation via a nebuliser (PL 10949/0085), authorised in the UK to Glaxo Wellcome UK Ltd on 01 March 1994 following a change of ownership from PL 00045/0123 authorised on 10 June 1981 and Ventolin Nebules 5mg/2.5ml Solution for inhalation via a nebuliser (PL 10949/0086) authorised in the UK to Glaxo Wellcome UK Ltd on 01 March 1994 following a change of ownership from PL 00045/0133 authorised on 15 May 1987.

No new non-clinical studies were conducted, which is acceptable given that the applications are based on being hybrid medicinal products of a reference products that have been licensed for over 10 years.

A biowaiver was submitted with these applications which was accepted. No bioequivalence or therapeutic equivalence studies were required, and none were provided with these applications.

The MHRA has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place for these products at all sites responsible for the manufacture, assembly and batch release of these products.

A Risk Management Plan (RMP) and a summary of the pharmacovigilance system have been provided with these applications and are satisfactory.

The RMS and CMSs considered that the applications could be approved at the end of procedure (Day 210) on 10 January 2019. After a subsequent national phase, licences were granted in the UK on 27 February 2019.

In this Repeat Use Procedure (IE/H/0713/001-003/E/001), authorisation is extended to CMSs AT, BE, CY, CZ, DK, ES, FI, HU, IT, NO, NL, PL, PT, RO, SK and SE on 10th October 2025.

The Summary of Product Characteristics for (SmPC) for this medicinal product is available on the HPRA's website at www.hpra.ie

Name of the product	Brodilaten 1.25 mg / 2.5 mL Nebuliser solution
Name(s) of the active substance(s) (INN)	Salbutamol
Pharmacotherapeutic classification (ATC code)	Andrenergics, inhalants. Selective β_2 adrenoreceptoragonists (R03AC02)
Pharmaceutical form and strength(s)	1.25 mg / 2.5 mL Nebuliser solution
Marketing Authorisation Number(s) in Ireland (PA)	PA1122/024/001
Marketing Authorisation Holder	Noridem Enterprises Limited
MRP/DCP No.	IE/H/0713/001/E/001
Reference Member State	IE
Concerned Member State	AT, BE, CY, CZ, DK, ES, FI, HU, IT, NO, NL, PL, PT, RO, SK, SE

II. QUALITY ASPECTS

II.1. Introduction

This application is for Brodilaten 1.25 mg / 2.5 mL Nebuliser solution, Brodilaten 2.5 mg / 2.5 mL Nebuliser solution and Brodilaten 5.0 mg / 2.5 mL Nebuliser solution.

These products consist of a clear and colourless solution.

In addition to salbutamol sulfate, the products also contain the excipients sodium chloride, water for injections and sulfuric acid. The finished products are supplied as packs of 10, 20, 30, 50 or 60 in low density polyethylene ampoules overwrapped in non-transparent protective aluminium pouches and packed in carton boxes. Each ampoule contains 2.5 mL of solution.

Satisfactory specifications and Certificates of Analysis have been provided for all packaging components. All primary packaging complies with the current European regulations concerning materials in contact with food.

II.2 Drug substance

The active substance is Salbutamol sulfate, an established active substance described in the European Pharmacopoeia, and is manufactured in accordance with the principles of Good Manufacturing Practice (GMP)

All aspects of the manufacture and control of the active substance are covered by a European Directorate for the Quality of Medicines and Healthcare (EDQM) Certificate of Suitability.

II.3 Medicinal product

P.1 Composition

2.5 mL of nebuliser solution contain 1.25 mg salbutamol (as salbutamol sulfate).

2.5 mL of nebuliser solution contain 2.5 mg salbutamol (as salbutamol sulfate).

2.5 mL of nebuliser solution contain 5.0 mg salbutamol (as salbutamol sulfate).

The excipients in the medicinal product are listed in section 6.1 of the SmPC.

A visual description of the product is included in section 3 of the SmPC.

P.2 Pharmaceutical Development

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

P.3 Manufacture of the Product

The product is manufactured in accordance with the principles of good manufacturing practice (GMP) at suitably qualified manufacturing sites.

A description and flow-chart of the manufacturing method has been provided.

Satisfactory batch formulae have been provided for the manufacture of the products, along with an appropriate account of the manufacturing processes. The manufacturing process has been validated according to relevant European guidelines and the process is considered to be sufficiently validated.

P.4 Control of Other Substances (Excipients/*Ancillary Substances*)

All excipients comply with either their respective European monographs. Satisfactory Certificates of Analysis have been provided for all excipients.

No excipients of animal or human origin are used in the finished products.

This product does not contain or consist of genetically modified organisms (GMO).

P.5 Control of Finished Product

The Finished Product Specification is based on the pharmacopoeial monograph for the Preparations for inhalation, and the tests and control limits are considered appropriate for this type of product.

The analytical methods used are described in sufficient detail and are supported by validation data.

Batch analytical data for a number of batches from the proposed production site(s) have been provided, and demonstrate the ability of the manufacturer to produce batches of finished product of consistent quality.

P.6 Packaging material

The approved packaging for this product is described in section 6.5 of the SmPC.

Evidence has been provided that the packaging complies with Ph. Eur. requirements and EU legislation.

P.7 Stability of the Finished Product

Stability data on the finished product in the proposed packaging have been provided in accordance with EU guidelines and support the shelf-life and storage conditions listed in sections 6.3 and 6.4 of the SmPC.

II.4 Discussion on Chemical, Pharmaceutical and Biological Aspects

The important quality characteristics of the product are well-defined and controlled. Satisfactory chemical and pharmaceutical documentation has been provided, assuring consistent quality of Brodilaten 1.25 mg / 2.5 mL Nebuliser solution, Brodilaten 2.5 mg / 2.5 mL Nebuliser solution and Brodilaten 5.0 mg / 2.5 mL Nebuliser solution.

III. NON-CLINICAL ASPECTS

III.1 Introduction

As the pharmacodynamic, pharmacokinetic and toxicological properties of salbutamol sulfate are well-known, no new non-clinical studies are required, and none have been provided. An overview based on the literature review is, thus, appropriate.

III.2 Pharmacology

No new pharmacology data were provided, and none were required for these applications.

III.3 Pharmacokinetics

No new pharmacokinetic data were provided, and none were required for these applications.

III.4 Toxicology

No new toxicology data were provided, and none were required for these applications.

III.5 Ecotoxicity/environmental risk assessment

Suitable justification has been provided for non-submission of an Environmental Risk Assessment. As these are hybrid applications of an already authorised products, it is not expected that environmental exposure will increase following approval of the Marketing Authorisations for the proposed products.

III.6 Discussion on the non-clinical aspects

The grant of marketing authorisations is recommended.

IV. CLINICAL ASPECTS

IV.1 Introduction

Salbutamol sulfate is a well known active substance with established efficacy and tolerability.

In accordance with the regulatory requirements, the applicant has provided a suitable biowaiver. No bioequivalence or therapeutic equivalence studies have been submitted with these applications.

The content of the SmPC approved during the decentralised procedure is in accordance with that accepted for the reference product Ventolin Nebules 2.5mg/2.5ml Solution for inhalation.

IV.2 Pharmacokinetics

No new pharmacokinetic data have been submitted for these applications and none were required.

IV.3 Pharmacodynamics

No new pharmacodynamic data have been submitted for these applications and none were required.

IV.4 Clinical Efficacy

No new efficacy data have been submitted for these applications and none were required.

Pharmaceutical equivalence was shown between the test and reference products. Therefore, in line with the guidelines, for the purposes of these applications, Brodilaten 1.25 m /2.5 mL, 2.5 mg/2.5 mL and 5.0 mg/2.5 mL Nebuliser solution can be considered therapeutically equivalent to Ventoline 1.25mg/2.5ml Solution pour inhalation par nebuliseur en recipient unidose, Ventolin Nebules 2.5mg/2.5ml Solution and Ventolin Nebules 5.0mg/2.5ml Solution, for inhalation via a nebuliser.

IV.5 Clinical Safety

No new safety data were submitted with these applications and none were required. The safety profile for these products is considered to be the same as Ventoline 1.25mg/2.5ml Solution pour inhalation par nebuliseur en recipient unidose, Ventolin Nebules 2.5mg/2.5ml Solution and Ventolin Nebules 5.0mg/2.5ml Solution, for inhalation via a nebuliser.

IV.6 Discussion on the clinical aspects

The grant of marketing authorisations is recommended for these applications.

V. OVERALL CONCLUSIONS

USERCONSULTATION

The package leaflet has been evaluated via a user consultation study in accordance with the requirements of Articles 59(3) and 61(1) of Directive 2001/83/EC. The results show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

Overall conclusion, benefit/risk assessment and recommendation

The quality of the products is acceptable, and no new non-clinical or clinical safety concerns have been identified.

Extensive clinical experience with salbutamol sulfate is considered to have demonstrated the therapeutic value of the products. The benefit/risk is, therefore, considered to be positive. The Summaries of Product Characteristics (SmPC), Patient Information Leaflet (PIL) and labelling are satisfactory and in line with current guidelines.

In accordance with Directive 2012/84/EU, the current approved UK versions of the SmPCs and PILs for these products are available on the MHRA website.